Zhenyue Li, Louis Choon Kit Wong, Rehena Sultana, Hui Jun Lim, Joey Wee-Shan Tan, Qiu Xuan Tan, Jolene Si Min Wong, Claramae Shulyn Chia, Chin-Ann Johnny Ong
{"title":"腹膜转移(PM)患者接受加压腹腔喷雾化疗(PIPAC)的生活质量(QoL)的系统评价。","authors":"Zhenyue Li, Louis Choon Kit Wong, Rehena Sultana, Hui Jun Lim, Joey Wee-Shan Tan, Qiu Xuan Tan, Jolene Si Min Wong, Claramae Shulyn Chia, Chin-Ann Johnny Ong","doi":"10.1515/pp-2021-0154","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has recently emerged as a palliative alternative for patients with unresectable peritoneal metastasis (PM). Quality of life (QoL) has increasingly been used as an endpoint to evaluate treatment outcomes. This review aims to identify evidence on how PIPAC would impact the QoL of PM patients.</p><p><strong>Content: </strong>A systematic review was performed on articles identified from Medline, EMBASE, PsycInfo, and Web of Sciences. A meta-analysis was conducted on further selected studies. ACROBAT-NRSI was attempted to assess the risk of bias (RoB).</p><p><strong>Summary: </strong>Nine studies using the EORTC QLQ-C30 questionnaire to assess QoL after repeated PIPAC cycles were identified. Majority was found to be moderately biased and a great extent of heterogeneity was observed. Four studies on PM from either gastric cancer (GC) or epithelial ovarian cancer (EOC) were included for meta-analysis. In 31 GC patients and 104 EOC patients, QoL remained stable in 13/14 and 11/14 EORTC QLQ-C30 scales. PIPAC was inferior to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in global QoL and functioning but superior in symptom reduction.</p><p><strong>Outlook: </strong>PIPAC is a well-tolerated option for most GC and EOC patients with irresectable PM. Future trials are warranted to confirm the findings.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"7 2","pages":"39-49"},"PeriodicalIF":1.4000,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166188/pdf/","citationCount":"8","resultStr":"{\"title\":\"A systematic review on quality of life (QoL) of patients with peritoneal metastasis (PM) who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC).\",\"authors\":\"Zhenyue Li, Louis Choon Kit Wong, Rehena Sultana, Hui Jun Lim, Joey Wee-Shan Tan, Qiu Xuan Tan, Jolene Si Min Wong, Claramae Shulyn Chia, Chin-Ann Johnny Ong\",\"doi\":\"10.1515/pp-2021-0154\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has recently emerged as a palliative alternative for patients with unresectable peritoneal metastasis (PM). Quality of life (QoL) has increasingly been used as an endpoint to evaluate treatment outcomes. This review aims to identify evidence on how PIPAC would impact the QoL of PM patients.</p><p><strong>Content: </strong>A systematic review was performed on articles identified from Medline, EMBASE, PsycInfo, and Web of Sciences. A meta-analysis was conducted on further selected studies. ACROBAT-NRSI was attempted to assess the risk of bias (RoB).</p><p><strong>Summary: </strong>Nine studies using the EORTC QLQ-C30 questionnaire to assess QoL after repeated PIPAC cycles were identified. Majority was found to be moderately biased and a great extent of heterogeneity was observed. Four studies on PM from either gastric cancer (GC) or epithelial ovarian cancer (EOC) were included for meta-analysis. In 31 GC patients and 104 EOC patients, QoL remained stable in 13/14 and 11/14 EORTC QLQ-C30 scales. PIPAC was inferior to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in global QoL and functioning but superior in symptom reduction.</p><p><strong>Outlook: </strong>PIPAC is a well-tolerated option for most GC and EOC patients with irresectable PM. Future trials are warranted to confirm the findings.</p>\",\"PeriodicalId\":20231,\"journal\":{\"name\":\"Pleura and Peritoneum\",\"volume\":\"7 2\",\"pages\":\"39-49\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2022-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166188/pdf/\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pleura and Peritoneum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/pp-2021-0154\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pleura and Peritoneum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/pp-2021-0154","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 8
摘要
背景:加压腹膜内气溶胶化疗(PIPAC)最近成为不可切除腹膜转移(PM)患者的一种姑息治疗选择。生活质量(QoL)越来越多地被用作评估治疗结果的终点。本综述旨在确定PIPAC如何影响PM患者生活质量的证据。内容:对来自Medline、EMBASE、PsycInfo和Web of Sciences的文章进行系统综述。对进一步选定的研究进行荟萃分析。ACROBAT-NRSI试图评估偏倚风险(RoB)。总结:9项研究使用EORTC QLQ-C30问卷评估重复PIPAC周期后的生活质量。发现大多数是中等偏倚，并观察到很大程度的异质性。四项关于胃癌(GC)或上皮性卵巢癌(EOC) PM的研究纳入meta分析。31例GC患者和104例EOC患者的生活质量在13/14和11/14 EORTC QLQ-C30量表中保持稳定。在总体生活质量和功能方面，PIPAC低于细胞减少手术联合腹腔热化疗(CRS/HIPEC)，但在症状减轻方面优于前者。展望:对于大多数胃癌和EOC不可切除PM患者，PIPAC是一种耐受性良好的选择。未来的试验有必要证实这些发现。
A systematic review on quality of life (QoL) of patients with peritoneal metastasis (PM) who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has recently emerged as a palliative alternative for patients with unresectable peritoneal metastasis (PM). Quality of life (QoL) has increasingly been used as an endpoint to evaluate treatment outcomes. This review aims to identify evidence on how PIPAC would impact the QoL of PM patients.
Content: A systematic review was performed on articles identified from Medline, EMBASE, PsycInfo, and Web of Sciences. A meta-analysis was conducted on further selected studies. ACROBAT-NRSI was attempted to assess the risk of bias (RoB).
Summary: Nine studies using the EORTC QLQ-C30 questionnaire to assess QoL after repeated PIPAC cycles were identified. Majority was found to be moderately biased and a great extent of heterogeneity was observed. Four studies on PM from either gastric cancer (GC) or epithelial ovarian cancer (EOC) were included for meta-analysis. In 31 GC patients and 104 EOC patients, QoL remained stable in 13/14 and 11/14 EORTC QLQ-C30 scales. PIPAC was inferior to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in global QoL and functioning but superior in symptom reduction.
Outlook: PIPAC is a well-tolerated option for most GC and EOC patients with irresectable PM. Future trials are warranted to confirm the findings.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
